The report lists Grasim Industries among the top losers, down 1.50-1.94%.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
1793 notes · 01 Oct 2026, 00:00 to 01 Nov 2026, 00:00 IST
The report lists Coal India among the top losers, down 1.50-1.94%.
Read this note →The report lists Asian Paints among the top losers, down 1.50-1.94%.
Read this note →The report lists Trent among the top gainers, up 2.42-6.78%.
Read this note →The report lists BSE (the exchange) among the top gainers, up 2.42-6.78%.
Read this note →The report lists Bajaj Auto among the top gainers, up 2.42-6.78%.
Read this note →The report lists Bharti Airtel among the top gainers, up 2.42-6.78%.
Read this note →The report lists Tata Consumer Products among the top gainers, up 2.42-6.78%.
Read this note →The report lists MAZDOCK under short build up in the market monitor section.
Read this note →The report lists AUBANK under short build up in the market monitor section.
Read this note →The report lists WAAREEENER under short build up in the market monitor section.
Read this note →The report lists UPL under long build up in the market monitor section.
Read this note →The report lists MOTILALOFS under long build up in the market monitor section.
Read this note →The report lists UNITDSPR under long build up in the market monitor section.
Read this note →The report states an ADD rating on Max Healthcare.
Read this note →The report states an ADD rating on Aster DM.
Read this note →The report states a BUY rating on Apollo Hospitals.
Read this note →The report maintains a BUY rating with a Sep-27 target price of INR 5,300, citing strong Q2FY27 execution with revenue up 17%, EBITDA up 50%, and earnings up 67%, driven by premiumization and raised FY27 P&A volume growth guidance to 30%.
Read this note →The report says IndiaMart delivered a moderate quarter with ARPU-led growth offsetting declining paying subscribers, maintaining ADD with a DCF-based TP of INR 1,900.
Read this note →The report says Acutaas Chemicals beat Q2 estimates on EBITDA/APAT but maintains SELL due to high near-term valuations, with TP of INR 2,427.
Read this note →The report says JK Cement delivered strong volume growth and EBITDA growth in Q2FY27, maintaining BUY with unchanged TP of INR 6,130.
Read this note →The report says MDL posted a disappointing quarter with declining revenue and EBITDA due to weak order book execution, but maintains a long-term constructive ADD rating with reduced multiple and TP of INR 2,300.
Read this note →The report says Tata Capital's Q2FY27 earnings beat estimates on lower credit costs and AUM growth despite NIM compression, maintaining ADD with a revised TP of INR 365.
Read this note →The report says SBI Life beat estimates on APE/VNB growth and margin expansion from product mix shift, maintaining a high-conviction BUY with revised TP of INR2,320.
Read this note →The report says L&T beat revenue and APAT estimates with record order book and robust order inflows, maintaining BUY with a revised SOTP target of INR 4,680.
Read this note →